KRAS and cancer: While several drugs targeting KRAS G12C mutant cancer sare under clinical trials [13], the KRASG12C mutation is very rare in gastric cancer: only 3.6% of KRAS mutant gastric cancer patients have the mutation according to combined cohort datasets in the cBioPortal (http://www.cbioportal.org).